A method for culturing pancreatic islet organoids using a culture medium containing small molecule compounds
By adding the small molecule compound S89 to the culture medium of pancreatic islet organoids, the problem of hypoxia damage in in vitro culture of pancreatic islet organoids was solved, promoting their long-term survival and insulin secretion, and improving the transplantation effect.
Patent Information
- Application Number
- CN202510618451.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-14
- Publication Date
- 2026-11-17
AI Technical Summary
Pancreatic organoids are susceptible to hypoxia damage during in vitro culture, leading to cell death and functional inactivation, which affects transplantation efficiency.
A culture medium containing the small molecule compound S89 at a concentration of 50-500 nM was used in combination with commonly used basic pancreatic organoid culture medium to promote the long-term survival of pancreatic organoids and their insulin secretion function.
It reduces oxidative damage to pancreatic organoids, enhances pancreatic β-cell activity, strengthens insulin secretion, and improves post-transplant glycemic response.
Smart Images

Figure BDA0005401806240000021 
Figure FDA0005401806230000011 
Figure HDA0005401806250000011
Abstract
Description
Technical Field
[0001] This invention belongs to the field of cell biology and organoids, specifically relating to a method for culturing pancreatic islet organoids using a culture medium containing small molecule compounds. Background Technology
[0002] Diabetes mellitus is a clinical syndrome characterized by disordered plasma glucose metabolism, caused by the combined effects of genetic and environmental factors. China has a high prevalence of diabetes, with an adult prevalence rate of 9.7% and 140 million patients, making it the third leading cause of chronic disease threat to human health after cancer and cardiovascular disease. Adult diabetes and its complications severely impact patients' health, causing approximately 6.7 million deaths annually among adults aged 20-79 due to diabetes or its complications. Islet transplantation is the optimal treatment for severe diabetes; however, donor shortages and graft dysfunction severely limit its clinical application.
[0003] In recent years, researchers have discovered that pancreatic organoids may mimic the important function of insulin secretion by the pancreas to treat diabetes, bringing new hope to diabetic patients. Pancreatic organoids are structurally and functionally similar to in vivo islets and can be cultured on a large scale in vitro, showing great promise in diabetes research. They can be used to study islet biology and simulate disease processes. Pancreatic organoids are stable and effective islet transplant substitutes, and are expected to become a highly promising cell replacement therapy for diabetes. However, due to hypoxia or insufficient nutrient supply, pancreatic organoids suffer oxidative damage in vitro, leading to islet cell death and inactivation, severely limiting transplantation efficiency. Therefore, overcoming hypoxia damage and achieving functional maintenance and long-term in vitro survival of pancreatic organoids are urgent scientific problems to be solved. Summary of the Invention
[0004] To address the problem of hypoxia-induced pancreatic islet cell death and inactivation, this invention aims to propose a method using small molecule compounds to reduce hypoxic injury and early death of pancreatic organoids, and to maintain or enhance pancreatic β-cell activity, thereby solving the aforementioned problems.
[0005] To solve the above problems, the present invention adopts the following technical solution:
[0006] In a first aspect, the present invention provides a pancreatic islet organoid culture medium that reduces oxidative damage and cell death in pancreatic islet organoids.
[0007] The pancreatic organoid culture medium provided by this invention contains the small molecule compound S89.
[0008] The structural formula of the small molecule compound S89 is shown below:
[0009]
[0010] The compound S89 described in this invention can be synthesized according to the method disclosed in the U.S. Patent "15-OXOSPIRAMILACTONEDERIVATIVES, PREPARATION METHODS AND USES THEREOF" (Authorization No.: US 10,112,918B2).
[0011] Furthermore, the concentration of the small molecule compound S89 in the pancreatic organoid culture medium is 50-500 nM, preferably 50 nM-100 nM, specifically such as 50 nM, 100 nM, 200 nM, 300 nM or 500 nM.
[0012] Furthermore, the pancreatic islet organoid culture medium also includes commonly used basic pancreatic islet organoid culture medium.
[0013] Furthermore, the pancreatic islet organoid culture medium may consist of the small molecule compound S89 and commonly used basic pancreatic islet organoid culture medium.
[0014] Furthermore, the formulation of the basic pancreatic organoid culture medium is as follows: using Advanced DMEM / F-12 as the basic medium, the following are added: 10 μM HEPES buffer, 100 μg / ml Primocin (Invitrogen, ant-pm-1), 2 μg / ml Heparin, 1 v / v% GlutaMAX (100×) (Gibco, 35050061), 2% B27 additive (50×) (Gibco, 10889038), 1 v / v% insulin-transferrin-selenium (ITS-G) (100×) (Gibco, 41400045), 50 ng / ml EGF (epidermal growth factor), 10 ng / ml FGF-2 (fibroblast growth factor), and 5 ng / ml VEGF (vascular endothelial growth factor).
[0015] Furthermore, the small molecule compound S89 is first dissolved in DMSO to prepare a 40mM stock solution. Before use, it is first diluted to 100μM with phosphate-buffered saline (PBS), and then diluted to the required final concentration in pancreatic organoid culture medium.
[0016] Secondly, the present invention provides a method for culturing pancreatic islet organoids.
[0017] The pancreatic islet organoid culture method provided by the present invention includes the following steps: culturing pancreatic islet organoids using the pancreatic islet organoid culture medium described in the first aspect of the present invention.
[0018] Furthermore, the cultivation time is 1-15 days, specifically 1 day, 2 days, 3 days, 4 days, 5 days, 7 days, and 14 days.
[0019] Furthermore, the pancreatic organoids are capable of secreting insulin and responding to high glucose stimulation.
[0020] The pancreatic islet organoids can be prepared using methods known in the art.
[0021] For example, a matrix gel bed can be made from matrix gel, and MIN6 cells can be incubated on it to spontaneously form pancreatic islet organoids.
[0022] According to an embodiment of the present invention, the specific preparation method of the pancreatic islet organoid is as follows: Matrigel is spread evenly on a 24-well plate at a rate of 100 μl / well at 4°C, and then the 24-well plate is placed in a 37°C incubator for 15 min to solidify the Matrigel. Mouse pancreatic β-cell line MIN6 cells are then incubated at a rate of 1×10⁻⁶ cells / well. 6 The cells were resuspended in the aforementioned islet organoid culture medium at a density of [density] / ml, seeded onto solidified Matrigel plates, and incubated in a CO2 incubator at 37°C for 8 hours. Spontaneously formed spherical cell clusters, i.e., islet organoids, were observed. Insulin secreted by these islet organoids could be detected using an ELISA kit and verified by insulin immunofluorescence. This insulin responded to high glucose stimulation; insulin secretion was induced under 20 mM high glucose conditions.
[0023] In the above method, the small molecule compound S89 can promote the long-term survival and insulin secretion function of pancreatic organoids in vitro, and can improve the blood glucose response after transplantation.
[0024] The above culture method can reduce oxidative damage and / or cell death in pancreatic organoids and improve pancreatic β-cell activity.
[0025] Pancreatic organoids cultured using the above method are also within the scope of protection of this invention.
[0026] The pancreatic organoids cultured using the above method can be used to prepare pancreatic islet grafts.
[0027] Human islets contain a rich vascular network, a crucial pathway for the transport of oxygen and nutrients. However, in vitro islets are prone to oxidative stress due to hypoxia and insufficient nutrient supply, leading to islet cell death or dysfunction. Premature islet cell death caused by hypoxia is also a major cause of islet transplantation failure. This invention addresses the hypoxia problem in current islet and islet organoid culture and transplantation, improving islet survival and insulin secretion function in vitro, and enhancing the therapeutic effect of islet transplantation on hyperglycemia. Attached Figure Description
[0028] Figure 1 This is an immunofluorescence image of mitochondrial fusion induced by S89 in pancreatic islet cells. The red fluorescence represents the mitochondrial outer membrane protein Tom20, which characterizes the mitochondrial outline. The left image shows pancreatic islet cells from the control group, and the right image shows cells treated with S89 100 nM for 24 hours.
[0029] Figure 2 This is a bright-field plot showing the in vitro promotion of pancreatic islet organoid growth by S89. The left plot is the control group, the middle plot is the result of S89 100 nM treatment for 5 days, and the right plot is a statistical chart of the relative projected area of pancreatic islet organoids (where the circles represent the projected area of the control group organoids, and the squares represent the projected area of the S89 group).
[0030] Figure 3 This is a fluorescence image showing the effect of S89 on the survival of pancreatic islet organoids. The first row represents live cells stained with calcein, and the second row represents dead cells stained with PI. From left to right, 1-5 represent: 1: control group; 2: S89 10 nM treatment for 3 days; 3: S89 50 nM treatment for 3 days; 4: S89 100 nM treatment for 3 days; 5: S89 500 nM treatment for 3 days.
[0031] Figure 4 RT-PCR diagram of key transcription factors for S89-induced ferroptosis.
[0032] Figure 5 This is an immunofluorescence image showing the effect of S89 on insulin secretion. The fluorescence in the image represents insulin. The left image is the control group, the middle image is the result of S89 100 nM treatment for 12 hours, and the right image is the result of S89 100 nM treatment for 24 hours.
[0033] Figure 6 Immunoblot images showing the effect of S89 on insulin secretion. Left: control group; Middle: S89 100 nM treatment for 12 hours; Right: S89 100 nM treatment for 24 hours.
[0034] Figure 7 A statistical chart showing how S89 promotes insulin secretion.
[0035] Figure 8 Add a statistical chart of the islet transplantation effect to S89. Detailed Implementation
[0036] As mentioned earlier, hypoxia-induced cell death and functional inactivation are key problems in the current culture of islet cells and islet organoids. Early cell death caused by hypoxia after transplantation of islets and islet organoids severely affects long-term therapeutic efficacy. Therefore, the inventors have conducted extensive research on improving the hypoxic state of islet organoids.
[0037] Based on the significant role of reducing oxidative damage in the future clinical treatment of severe diabetes with pancreatic islet organoid transplantation, the inventors utilized advanced pancreatic islet organoid assessment technology to comprehensively evaluate the biomedical functions and clinical translation prospects of islet organoids. During the growth of islet organoids, the small molecule compound S89 was added to reduce cell death caused by in vitro hypoxia by altering the redox levels of blood islet cells, thus promoting islet organoid growth. Based on this, the inventors further discovered that using a matrix gel bed made of matrix gel, and incubating MIN6 cells on it to spontaneously form islet organoids, adding the S89 compound to the culture medium of these islet organoids can promote long-term survival and insulin secretion, prevent islet organoid hypoxia after transplantation, and demonstrate a complete glucose response mechanism after transplantation.
[0038] The present invention will now be described in further detail with reference to specific embodiments. The given embodiments are merely illustrative of the invention and not intended to limit its scope. The embodiments provided below can serve as a guide for further improvements by those skilled in the art and do not constitute a limitation on the invention in any way.
[0039] Unless otherwise specified, the experimental methods used in the following examples are conventional methods, performed according to the techniques or conditions described in the literature in this field or according to the product instructions. Unless otherwise specified, the materials and reagents used in the following examples are commercially available.
[0040] The compound S89 described in this invention can be synthesized according to the method disclosed in the U.S. Patent "15-OXOSPIRAMILACTONEDERIVATIVES, PREPARATION METHODS AND USES THEREOF" (Authorization No.: US 10,112,918B2).
[0041] The MIN6 used in this invention is derived from a commercially available cell line.
[0042] Example 1: Culture of pancreatic organoids
[0043] I. Reagents required for culture:
[0044] Culture medium A: Advanced DMEM / F-12 (basal medium), 10 μM HEPES, 2% Promocin, 2 μg / ml Heparin, 1% GlutaMAX, 2% B27, 1% ITS, 50 ng / ml EGF, 10 ng / ml FGF-2, 5 ng / ml VEGF.
[0045] Culture medium B: Culture medium A + S89, with S89 concentrations of 10 nM, 50 nM, 100 nM, 200 nM, and 500 nM.
[0046] II. Cultivation methods and operating procedures:
[0047] (1) At 4℃, take 20 μl of Matrigel and spread it evenly in the middle of the bottom of the wells of a 24-well plate, avoiding contact with the well walls. Place the 24-well plate in a 37℃ CO2 incubator for 30 minutes to solidify the Matrigel.
[0048] (2) MIN6 cells were cultured to 70% contact and then digested into single cells using pre-warmed TrypLE Express. After centrifugation, the cells were resuspended in culture medium A at 0.5 × 10⁻⁶. 5 cells / cm 2 ~2×10 5 cells / cm 2 The samples were inoculated at a density on pre-coated Matrigel culture plates and incubated for 1 day.
[0049] (3) Replace the control group with fresh culture medium A and the experimental group with culture medium B, and culture for 5 days respectively.
[0050] III. Detection Methods:
[0051] 1. Immunofluorescence detection of mitochondrial morphology in pancreatic islet cells
[0052] (1) Culture MIN6 cells on a suitable coverslip. When the cells grow to 70-80% density, gently wash the cells 2-3 times with pre-cooled PBS (phosphate buffer) to remove culture medium and impurities.
[0053] (2) Add cell culture medium containing 4% paraformaldehyde and fix in a cell culture incubator for 10 minutes. Wash with PBS 2-3 times after fixation.
[0054] (3) Soak 0.1% Triton X-100 in PBS solution at room temperature for 5-15 minutes, then wash with PBS 2-3 times.
[0055] (4) Block with 5% bovine serum albumin in PBS solution for 60 minutes.
[0056] (5) Add antibody against mitochondrial outer membrane protein Tom20 diluted with antigen diluent and incubate overnight at 4°C, then wash 3 times with PBS. Add secondary antibody anti-mouse IgG labeled with fluorescein 555 diluted with antigen diluent and incubate at room temperature in the dark for 30 minutes, then wash 3 times with PBS.
[0057] (6) Add a mounting medium to the sample, cover with a coverslip, and observe under a fluorescence microscope. Tom20 fluorescence characterizes mitochondrial morphology, such as... Figure 1 As shown, S89 induces mitochondrial fusion in pancreatic islet cells.
[0058] 2. Bright field morphology detection
[0059] Bright-field micrographs were taken using a phase-contrast microscope at key time points to observe the morphology of pancreatic islet organoids.
[0060] (1) Number of pancreatic islet organoids
[0061] Bright-field micrographs were taken using a phase-contrast microscope at key time points, and the number of organoids in nine fields of view was counted to compare the number of pancreatic islet organoids.
[0062] Digest the organoids using pre-warmed TrpLE Express at 37°C for 6-10 minutes, repeatedly pipetting until single cells are formed. Add 2 mL of culture medium to neutralize the digestion solution, centrifuge at 300 rcf for 3 minutes, and discard the supernatant. Resuspend the cells in 2 mL of DPBS, and add 10 μL of the cell suspension to a cell counting chamber. Count the cells under a microscope.
[0063] (2) Measurement of pancreatic islet organoid size
[0064] Using ImageJ software, set the scale according to the image scale bar. Use the "Circle" tool to circle the shape of each organoid, and use the "Measure" tool to calculate the surface area of the organoid projection. Plot a scatter plot of the measured organoid surface areas.
[0065] 3. Detection of organoid cell viability
[0066] Calcein / PI staining: Pancreatic islet organoids were seeded into cell culture plates, and controls and S89 drug were added for treatment. Before the experiment, calcein-AM and PI were diluted to appropriate concentrations with serum-free medium or PBS buffer (calcein-AM working concentration: 2 μM, PI working concentration: 1 μg / mL). The two dyes were then mixed in a certain ratio to prepare a staining buffer. An appropriate amount of staining buffer was added to the cell suspension to make the final cell concentration 1×10⁵-1×10⁶ cells / mL. After gentle mixing, the cells were incubated at 37°C in the dark for 60 minutes to allow the dye to fully penetrate the cells. The cells were washed 2-3 times with PBS buffer and observed under a fluorescence microscope.
[0067] 4. Quantitative RT-PCR detection of ferroptosis transcription factor
[0068] Cell control and MIN6 cells from Example 1 were seeded in culture dishes and cultured to 80% confluence under suitable conditions. The culture medium was then discarded, and the cells were gently washed 2-3 times with PBS buffer to remove residual medium. An appropriate amount of lysis buffer (TRIzol) was added to lyse the cells thoroughly. The RNA extraction kit was followed according to the manufacturer's instructions, including chloroform extraction, isopropanol precipitation, and ethanol washing of the RNA precipitate. After centrifugation, the supernatant was discarded, and the precipitate was air-dried. The RNA precipitate was dissolved in an appropriate amount of DEPC water, and the RNA concentration and purity were determined.
[0069] A reverse transcription reaction system, including RNA template, reverse transcriptase, Oligo(dT) primers, dNTP mixture, and buffer, was prepared on ice. After gentle mixing and brief centrifugation, the mixture was placed in a PCR instrument for reverse transcription. A PCR reaction system, including cDNA template, specific PCR primers, dNTP mixture, Taq polymerase, and buffer, was prepared on ice. Ferrocyte transcription factors were amplified through cycles of denaturation, annealing, and extension. A fluorescent probe was added to the PCR reaction system, and the accumulation of PCR products was monitored in real time by detecting changes in the fluorescence signal. The data were analyzed using appropriate software to obtain the relative expression level of the target gene.
[0070] IV. Test Results
[0071] 1. Immunofluorescence detection of mitochondrial morphology
[0072] Figure 1 The left image shows the mitochondria of pancreatic islet cells from the control group, while the right image shows the mitochondria of pancreatic islet cells after treatment with S89 100nM for 24 hours. It can be seen that after S89 treatment of pancreatic islet cells, the mitochondria fused together, changing from fragmented to linear, with a more complete structure.
[0073] 2. Bright field morphology detection
[0074] Figure 2 The diagram shows that the pancreatic islet organoids obtained using this method (example) are more numerous and larger than those obtained using the control method shown in the left diagram (comparative example).
[0075] 3. Detection of organoid cell viability
[0076] The cell viability of organoids was measured in both the examples and comparative examples, and the results are as follows: Figure 3 As shown, the proportion of live cells in the organoids of the embodiment is greater than that of the comparative embodiment, indicating that the embodiment effectively improves the cell survival rate in the endpoint organoids.
[0077] 4. Detection of organoid ferroptosis transcription factors
[0078] Quantitative RT-PCR results as follows Figure 4As shown, in the embodiments, S89 reduces ferroptosis transcription factors GPX4 and SLC7A11, indicating that S89 improves islet cell survival by inhibiting islet cell ferroptosis.
[0079] Example 2: Measurement of Insulin Secretion
[0080] 1. Immunofluorescence detection of insulin expression in pancreatic organoids.
[0081] MIN6 cells were cultured on pre-coated Magrigel coverslips. Islet organoids spontaneously formed in the control group and in the islet organoid culture medium containing S89 (Example 1). On day 7, organoid culture medium containing 4% paraformaldehyde was added, and the cells were fixed in a cell culture incubator for 10 minutes. After fixation, the cells were washed 2-3 times with PBS. Permeabilization was performed with 0.1% Triton X-100 in PBS solution at room temperature for 5-15 minutes, followed by 2-3 washes with PBS. Blocking was performed with 5% bovine serum albumin in PBS solution for 60 minutes. Anti-mouse insulin antibody diluted with antigen dilution was added and incubated overnight at 4°C, followed by 3 washes with PBS. The next day, anti-mouse IgG labeled with fluorescein 555 diluted with antigen dilution was added and incubated at room temperature in the dark for 30 minutes, followed by 3 washes with PBS. Mounting tablets were added, coverslips were placed, and the cells were observed under a fluorescence microscope. The fluorescence intensity of insulin characterizes insulin secretion. Figure 5 As shown, S89 increases insulin secretion.
[0082] 2. Detection of insulin expression by Western blotting
[0083] Islet organoids spontaneously formed in the culture medium of the control group and the example containing S89 were collected. Proteins were lysed, and protein concentration was determined using the Coomassie Brilliant Blue G250 method. SDS-PAGE protein electrophoresis gels were prepared, transferred to membranes, blocked, and treated with insulin antibody primary and secondary antibodies. ECL color development and exposure were performed, and insulin expression levels were indicated by the developed bands. Figure 6 As shown, S89 increases insulin secretion.
[0084] 3. Detection of insulin concentration in supernatant using enzyme-linked immunosorbent assay (ELISA).
[0085] (1) Add S89 (0-300 nM) to MIN6 cells cultured in two dimensions and to organoids spontaneously formed from MIN6 cells.
[0086] (2) Collect cell culture supernatants from experimental and comparative cases on days 1, 2, 5, 7 and 14.
[0087] (3) ELISA assay to detect human insulin concentration in supernatant
[0088] a. Remove the kit from the refrigerator and allow it to equilibrate at room temperature (25-28℃) for 20 minutes.
[0089] b. Add the standard diluent to one vial of standard according to the volume indicated on the standard label, and incubate at room temperature for 15 minutes. Then gently mix and pipette several times to completely dissolve the standard, so that the final concentration of the standard reaches 200 mIU / L.
[0090] c. Take five clean 1.5 mL centrifuge tubes and pre-add 250 μL of standard diluent to each tube. Through serial dilution of the standard, obtain six standard concentrations of 200, 100, 50, 25, 12.5, and 6.25 mIU / L. Finally, add the diluted standard to the wells of the pre-coated plate in sequence. The standard diluent is added directly as the 0 mIU / L concentration, for a total of seven standard concentrations.
[0091] d. Add 25 μl of cell culture supernatant or standard of different concentrations to the corresponding wells after culturing for different times.
[0092] e. Immediately add 100 μl of horseradish peroxidase-labeled human insulin antibody to each well. Seal the wells with a clear sealing film and incubate at room temperature for 120 minutes.
[0093] f. Wash the plate 5 times, and pat it dry on thick absorbent paper on the last wash.
[0094] g. Add 100 μl of TMB solution as the colorimetric reagent to each well, seal the wells with white sealing film, and incubate at room temperature in the dark for 10 minutes. Incubation can continue until the standard and sample show a very significant color change.
[0095] h. Add the stop solution at 50 μl / well, mix well, and immediately measure the A450 value. Calculate the insulin concentration in the sample based on the standard curve.
[0096] like Figure 7 As shown, the insulin content in organoid culture medium is higher than that in two-dimensional cultured cell lines. In both cell culture methods, S89 can increase insulin secretion.
[0097] Example 3: Islet Transplantation in Diabetic Mice
[0098] 1. Select healthy, age-appropriate mice, typically C57BL / 6 mice. Place the mice in a standard animal husbandry environment and allow them to acclimatize to the environment for at least one week before the experiment begins.
[0099] 2. A diabetic model was established in mice by intraperitoneal injection of streptozotocin (STZ). Specifically, after fasting for 12 hours, mice were given a single intraperitoneal injection of STZ solution at a dose of 50 mg / kg. Blood glucose levels were closely monitored after injection. Mice with stable blood glucose levels above 16.7 mmol / L, accompanied by symptoms such as polydipsia, polyphagia, polyuria, and weight loss, were considered to have successfully established a diabetic model.
[0100] 3. Select healthy mice of the same strain as donors and remove their pancreas under sterile conditions. First, place the pancreas in a digestive solution containing collagenase P and digest it with shaking at 37°C for 15-20 minutes.
[0101] 4. After digestion, a suspension containing islets was obtained by filtration and centrifugation. The cell suspension was then carefully spread on Ficoll gradient stratification medium and centrifuged (1000g, 20 minutes) to collect the purified islet layer.
[0102] 5. The isolated mouse islets were seeded onto a matrix gel according to the culture method described in Example 1, and culture medium A or culture medium B was added to form islet organoids. The concentration of S89 in culture medium B was 200 nM. The islets were cultured in vitro for 48 hours.
[0103] 6. Collect islet organoids and count them under a microscope. In a clean bench, carefully cut open the abdominal skin and muscles of diabetic model mice with ophthalmic scissors to expose the kidneys. Gently pull the kidneys out of the abdominal cavity, taking care to avoid damaging surrounding tissues and blood vessels. Using a microsyringe, draw up an appropriate amount of the prepared purified islet suspension. On the outer side of the lower pole of the kidney, gently prick a small hole in the surface of the renal capsule with the syringe needle. Then, slowly inject a suspension of 150 islet organoids under the renal capsule, ensuring that the islets are evenly distributed within the renal capsule.
[0104] 7. After injection, quickly remove the needle and gently press the injection site with a cotton swab for a moment to prevent pancreatic fluid leakage. Then, place the kidney back into the abdominal cavity and suture the abdominal muscle and skin incision. After surgery, place the mouse in a warm, clean, and quiet environment and closely observe its mental state, diet, water intake, and urination.
[0105] 8. At different time points after surgery (e.g., day 2, day 4, day 6), tail vein blood was collected from mice, and fasting blood glucose levels were measured using a glucometer to evaluate the therapeutic effect of islet transplantation on diabetes. Figure 8 As shown in the figure (culture medium refers to culture medium A), transplantation of pancreatic islet organoids can reduce blood glucose in diabetic mice, and S89 can further reduce blood glucose levels.
[0106] The present invention has been described in detail above. For those skilled in the art, the invention can be practiced in a wide range of ways with equivalent parameters, concentrations, and conditions without departing from its spirit and scope, and without requiring unnecessary experiments. Although specific embodiments have been given, it should be understood that further modifications can be made to the invention. In summary, according to the principles of the invention, this application is intended to include any changes, uses, or improvements to the invention, including changes made using conventional techniques known in the art that depart from the scope disclosed herein. Some of the essential features can be applied within the scope of the following appended claims.
Claims
1. A pancreatic islet organoid culture medium that reduces oxidative damage and cell death in pancreatic islet organoids, containing the small molecule compound S89; The structural formula of the small molecule compound S89 is shown below:
2. The pancreatic islet organoid culture medium according to claim 1, characterized in that: The concentration of the small molecule compound S89 in the pancreatic organoid culture medium is 50-500 nM, preferably 50 nM-100 nM.
3. The pancreatic islet organoid culture medium according to claim 1 or 2, characterized in that: The pancreatic islet organoid culture medium also includes a basic pancreatic islet organoid culture medium.
4. The pancreatic islet organoid culture medium according to claim 3, characterized in that: The basic pancreatic organoid culture medium consisted of: 10 μM HEPES buffer, 100 μg / ml Primocin (Invitrogen, ant-pm-1), 2 μg / ml Heparin, 1 v / v% GlutaMAX (100×) (Gibco, 35050061), 2% B27 additive (50×) (Gibco, 10889038), 1 v / v% Insulin-Transferrin-Selenium (ITS-G) (100×) (Gibco, 41400045), 50 ng / ml EGF (epidermal growth factor), 10 ng / ml FGF-2 (fibroblast growth factor), 5 ng / ml VEGF (vascular endothelial growth factor), with the remainder being Advanced DMEM / F-12 medium.
5. A method for culturing pancreatic islet organoids, comprising the following steps: culturing pancreatic islet organoids using the pancreatic islet organoid culture medium according to any one of claims 1-4.
6. The method according to claim 5, characterized in that: The culture time is 1-14 days.
7. The method according to claim 5 or 6, characterized in that: The method can reduce oxidative damage and / or cell death in pancreatic organoids, or the method can improve pancreatic β-cell activity.
8. Pancreatic islet organoids cultured by the method of any one of claims 5-7.
9. The use of the pancreatic islet organoids according to claim 8 in the preparation of pancreatic islet grafts.
Citation Information
Patent Citations
15-oxospiramilactone derivatives, preparation method and uses thereof
US10112918B2
